<DOC>
	<DOCNO>NCT02745132</DOCNO>
	<brief_summary>The overall aim study evaluate prevalence cognitive impairment brain anomaly Chronic Hepatitis C infect individual investigate likely change cognition brain structure function treatment Direct-acting Antivirals ( DAAs ) .</brief_summary>
	<brief_title>Cognitive Impairments Chronic Hepatitis C Patients Potential Reversibility With New Agents ( CICHepC )</brief_title>
	<detailed_description>Design : Prospective interventional study . Chronic HCV infect patient go initiate DAA-based antiviral regimen accord clinical practice recruit participate study . Patients treat accord current national international guideline treatment HCV chronic hepatitis . The participation study influence neither indication de treatment type treatment prescribe . The intervention study refers performance extraordinary neuro-psychological evaluation MRI study different time along study . Patients method : This study perform cohort 80 patient CHC ( ≤ F3 ) . The number subject require test effect sufficient power entire cortex varies cortical measure ( cortical thickness : N=39 , surface area : N=21 , volume : N=81 ; 10mm smoothing , power=0.8 , α =0.05 ) . For subcortical region number 16 76 subject , depend region ( Liem et al. , 2015 ) . Sample size calculation perform functional magnetic resonance use value medium Cohen 's effect size 0.6 0.7 yield sample size 88 , 66 respectively achieve 80 % power significance level 0.05 ( Guo et al. , 2012 ) . Therefore , sample size estimate project would yield enough power detect small medium effect size . The following study conduct : 1 . - Cognitive assessment : The assessment widely-used neuropsychological test battery may yield summary score domain : attention reaction time ( Continuous Performance Test ( CPT ) , work memory ( digits forward backward WAIS-III subtest ) , information processing speed ( digit symbol WAIS-III subtest Trail make test Part A ) , verbal fluency ( letter FAS category animal subtest ) , learn memory ( Rey Auditory 2.- Verbal Learning Test ( RAVLT ) Rey Copy Figure ( RCF ) ) , motor functioning ( Grooved Pegboard ) executive function ( Tower London , Trail make test Part B Stroop color-word test ) . 2 . - MRI scanning : Imaging data acquire neurorradiology section Hospital Marques de Valdecilla , 3T MRI scanner ( Achieva , Philips Medical Systems , Best , The Netherlands ) Neuroradiology Department `` Marques de Valdecilla '' University Hospital . Subjects undergo 30 minute protocol include high resolution T1- weight image , 64 direction DWI sequence A BOLD rest state fMRI sequence . 3 . - MRI data analysis : It involve structural , diffusion functional MRI analysis . These analysis conduct Neuroimaging Platform IDIVAL . 3.1.- Structural MRI : use software FreeSurfer ( http : //freesurfer.net/ ) quantify volume subcortical structure ( amygdala , hippocampus , thalamus , putamen , globus pallidus , caudate nucleus ) area , thickness , volume 34 cortical structure ( Desikan-Killiany atlas ) . 3.2.- Diffusion MRI : use FSL 's TBSS Probtracx tool http : //www.fmrib.ox.ac.uk/fsl/index.html ) compare fractional anisotropy value ( measure base restrict movement water molecule ) whole brain voxelwise analysis identify region ( cluster ) white matter disorganize . Also perform fiber track study connectivity different brain area . 3.3.- Functional MRI ( fMRI ) : rest state fmri use evaluate regional interaction occur non perform specific task . This analysis carry use SPM software http : //www.fil.ion.ucl.ac.uk/spm/ ) toolbox PRONTO ( http : //www.mlnl.cs.ucl.ac.uk/pronto ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>CHC patient 1875 year old Liver fibrosis ≤ F3 Fibroscan/liver biopsy Naive previous failure treatment Accept study sign CI Does meet criterion VIH viral coinfection Hepatocarcinoma Other systemic inflammatory disease ( i.e . RA , etc ) Neurodegenerative disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic , Cognition Disorders</keyword>
	<keyword>Neurocognition Disorders</keyword>
	<keyword>Cognitive Impairments</keyword>
	<keyword>Diffusion Magnetic Resonance Imaging</keyword>
	<keyword>MRI functional</keyword>
	<keyword>Verbal fluency</keyword>
</DOC>